Intravitreal bevacizumab versus ranibizumab for the treatment of retinal angiomatous proliferation.

PURPOSE: To evaluate the effects of intravitreal bevacizumab and ranibizumab treatments in retinal angiomatous proliferation (RAP). METHODS: Fifty patients affected by RAP were randomly assigned either to intravitreal bevacizumab injection (IVBI) or intravitreal ranibizumab injection (IVRI). After a loading phase including three consecutive monthly injections, the retreatment was administered in cases of persistent RAP. The primary outcome measures were the mean changes in BCVA between the two treatment groups, and the proportion of eyes gaining 1 and 3 lines at the end of the follow-up. Secondary outcomes included central macular thickness (CMT) changes and progression to more advanced stages of RAP. RESULTS: Fifty patients affected by stage 1 and 2 RAP were recruited. Twenty-six and 24 patients received IVBI and IVRI, respectively. At the baseline, mean best corrected visual acuity (BCVA) values were 0.59 ± 0.21 (LogMAR ± SD, approximately corresponding to 20/80 Snellen Equivalent-SE) in IVBI group and 0.66 ± 0.33 (approximately 20/90 SE) in IVRI group with no statistical difference. At 12-month examination, both groups showed a statistically significant improvement in the BCVA, with a final mean value of 0.43 ± 0.24 (approximately 20/54 SE) in IVBI group and 0.50 ± 0.32 (approximately 20/63 SE) in the IVRI group. A BCVA gain of 1 and 3 lines was registered in 20 and 8 eyes, respectively, in the IVBI group. Similarly, 17 and 7 eyes showed an improvement of 1 or 3 lines, respectively, in the IVRI group. The CMT reduced significantly from baseline to 12-month examination in both groups. A lower proportion of eyes with complete pigment epithelium detachment resolution was noted in the IVBI group than in the IVRI group (40% versus 90%). CONCLUSIONS: Our study shows that both IVBI and IVRI are equally effective in improving the BCVA over a 1-year follow-up in eyes affected by stage 1 and 2 RAP.

Effect of posture on the diurnal variation in clinically significant diabetic macular edema.

PURPOSE: To investigate the role of posture and other systemic factors in the diurnal variation of clinically significant diabetic macular edema (CSDME). METHODS: Ten eyes of 10 diabetic subjects with CSDME underwent four OCT foveal thickness measurements with StratusOCT at 9 AM and 12, 3, and 6 PM consecutively on two different days, with the subject in an upright position on one and in a recumbent position on the other. For the "recumbent-position" measurements, the patients were admitted the night before and remained in bed during the entire day of testing. Clinical laboratory results at baseline included HbA1c, urinary albumin, and serum creatinine. Refraction and Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity were also measured before each OCT measurement was taken. Variations in blood pressure, body temperature, plasma glucose, renin, aldosterone, and cortisol levels were measured and then correlated with macular thickness. RESULTS: Foveal thickening decreased in all cases over the course of the day. The decrease, however, was significantly greater for the upright-position measurements (relative mean +/- SD decrease of 20.6% +/- 6.5% in the upright position and 6.2% +/- 4.6% in the recumbent position). Visual acuity improved by at least 1 ETDRS line in three eyes in the upright position as opposed to only one eye in the recumbent position. There seemed to be no association between any of the systemic factors studied and foveal thickening, with the exception of cortisol. CONCLUSIONS: The results support the hypothesis that posture and hydrostatic pressure play a major role in determining time-related shifts in CSDME and suggest that the forces of Starling's law can in part, account for CSDME formation.

Diurnal variation in clinically significant diabetic macular edema measured by the Stratus OCT.

PURPOSE: To investigate diurnal variation in clinically significant macular edema (CSME) using the Stratus OCT (Carl Zeiss Meditec). METHODS: Fifteen eyes of 15 diabetic patients with CSME and 10 healthy subjects (controls) underwent four optical coherence tomography (OCT) measurements of macular thickness with the fast macular thickness mapping protocol of the Stratus OCT at 9 am, 12 pm, 3 pm, and 6 pm. Early Treatment Diabetic Retinopathy Study visual acuity and refraction data were also collected at each time. Retinal thickness measurements from each of the nine macular Early Treatment Diabetic Retinopathy Study areas of the retina map, visual acuity, and refraction were plotted over time. RESULTS: Mean retinal thickness remained unchanged in all retinal sectors over the course of the day for the controls and the 6 diabetic patients with a baseline foveal thickness of <300 mum, and it significantly decreased in 7 of the 9 retinal sectors for the 9 diabetic patients with a baseline foveal thickness of > or =300 microm (ANOVA model for repeated measures). In these patients, the mean initial foveal thickening +/- SD of 211 +/- 104 microm was reduced by an average of 6.1%, 15.2%, and 21.2% at 12 pm, 3 pm, and 6 pm, respectively. Two of these nine patients also had an increase in visual acuity without change in refraction. There were no changes in refractive errors over the course of the study in the two groups. A positive correlation between initial central thickening and decrease in thickness was found (r = 0.732; P = 0.002). CONCLUSION: This study suggests that macular thickening, as measured by the Stratus OCT, may spontaneously decrease in some patients with more severe CSME over the course of the day, and it confirms previous findings. However, in our study, the entity of this decline was relatively small and not relevant from a clinical standpoint.